There is a growing body of evidence on the role of inflammation in predicting heart health.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Sandeep Kulkarni, CEO of Tourmaline Bio, about addressing inflammation, and also the impact of AI and GLP-1s on cardiology clinical trials and drug development.

Kulkarni also discusses Tourmaline’s IL-6 inhibitor for atherosclerotic cardiovascular disease, and his hopes for the future of this field of research.

You can listen to episode 221 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.